{"disease":{"id":"zollinger-ellison-syndrome","name":"Zollinger-Ellison syndrome","therapeutic_area":"","data":{},"enrichment_level":0,"last_enriched_at":null,"visit_count":0,"created_at":"2026-04-19T18:31:21.150Z","updated_at":"2026-04-19T18:39:44.960Z","meddra_pt":null,"meddra_code":null,"icd10_codes":null,"synonyms":[],"prevalence_global":null,"prevalence_us":null,"marketed_drug_count":16,"pipeline_drug_count":0,"trial_count":0},"drugs":{"marketed":[{"drug_id":"omeprazole","indication_name":"Zollinger-Ellison syndrome","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Prilosec","generic_name":"omeprazole","company_name":"AstraZeneca (originally Astra AB)","drug_phase":"marketed","molecular_target":"ATP-binding cassette sub-family G member 2, Cytochrome P450 1A2, Cytochrome P450 2C19","drug_class":"Proton pump inhibitor (PPI)","quality_score":50,"revenue":"1041.0","mechanism":"Irreversibly inhibits the hydrogen-potassium ATPase (proton pump) in gastric parietal cells, potently suppressing stomach acid secretion."},{"drug_id":"ranitidine","indication_name":"Zollinger-Ellison syndrome","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Zantac","generic_name":"ranitidine","company_name":"GSK (originally Glaxo)","drug_phase":"marketed","molecular_target":"Multidrug and toxin extrusion protein 1, Acetylcholinesterase, Histamine H2 receptor","drug_class":"H2 receptor antagonist","quality_score":27,"revenue":null,"mechanism":""},{"drug_id":"famotidine","indication_name":"Zollinger-Ellison syndrome","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pepcid","generic_name":"famotidine","company_name":"Generic (originally Yamanouchi/Merck)","drug_phase":"marketed","molecular_target":"Multidrug and toxin extrusion protein 1, Multidrug and toxin extrusion protein 2, Solute carrier family 22 member 2","drug_class":"Histamine-2 Receptor Antagonist [EPC]","quality_score":56,"revenue":null,"mechanism":"Competitively blocks histamine H2 receptors on gastric parietal cells, reducing basal and stimulated acid secretion."},{"drug_id":"prevacid","indication_name":"Zollinger-Ellison syndrome","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Prevacid","company_name":"Vanderbilt University Medical Center","drug_phase":"marketed","molecular_target":"ATP-binding cassette sub-family G member 2, Cytochrome P450 2C19, Cytosolic endo-beta-N-acetylglucosaminidase","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"esomeprazole","indication_name":"Zollinger-Ellison syndrome","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Nexium","generic_name":"esomeprazole","company_name":"AstraZeneca","drug_phase":"marketed","molecular_target":"Potassium-transporting ATPase","drug_class":"Proton pump inhibitor (PPI)","quality_score":24,"revenue":null,"mechanism":""},{"drug_id":"pantoprazole","indication_name":"Zollinger-Ellison syndrome","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Protonix","generic_name":"pantoprazole","company_name":"Generic (originally Byk Gulden/Altana/Nycomed)","drug_phase":"marketed","molecular_target":"ATP-binding cassette sub-family G member 2, Fatty acid synthase, Multidrug and toxin extrusion protein 1","drug_class":"Proton pump inhibitor (PPI)","quality_score":58,"revenue":null,"mechanism":"Irreversibly inhibits the gastric proton pump (H+/K+ ATPase), suppressing stomach acid secretion."},{"drug_id":"protonix-iv","indication_name":"Zollinger-Ellison syndrome","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pantoprazole Sodium","generic_name":"Pantoprazole Sodium","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"(H+, K+)-ATPase enzyme","drug_class":"Proton pump inhibitor (PPI)","quality_score":69,"revenue":null,"mechanism":"Pantoprazole suppresses gastric acid by covalently binding the (H+, K+)-ATPase enzyme at parietal cells."},{"drug_id":"aciphex","indication_name":"Zollinger-Ellison syndrome","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Aciphex","company_name":"University of Utah","drug_phase":"marketed","molecular_target":"Sterile alpha and TIR motif-containing protein 1, ATP-binding cassette sub-family G member 2, Adenosine receptor A3","drug_class":"","quality_score":30,"revenue":null,"mechanism":null},{"drug_id":"rabeprazole-40-mg","indication_name":"Zollinger-Ellison Syndrome","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Rabeprazole 40 mg","generic_name":"rabeprazole-40-mg","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"H+/K+ ATPase","drug_class":"Proton Pump Inhibitor","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"cimetidine","indication_name":"Zollinger-Ellison syndrome","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tagamet","generic_name":"CIMETIDINE","company_name":"","drug_phase":"marketed","molecular_target":"Histamine H2 receptor","drug_class":"Histamine-2 Receptor Antagonist [EPC]","quality_score":65,"revenue":null,"mechanism":""},{"drug_id":"rabeprazole","indication_name":"Zollinger-Ellison syndrome","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aciphex","generic_name":"rabeprazole","company_name":"Waylis","drug_phase":"marketed","molecular_target":"Potassium-transporting ATPase","drug_class":"Proton Pump Inhibitor","quality_score":80,"revenue":null,"mechanism":"Aciphex works by irreversibly inhibiting the potassium-transporting ATPase enzyme in the stomach lining, reducing acid production."},{"drug_id":"rabeprazol","indication_name":"Zollinger-Ellison syndrome","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Rabeprazol","company_name":"Janssen-Cilag, S.A.","drug_phase":"discontinued","molecular_target":"Sterile alpha and TIR motif-containing protein 1, ATP-binding cassette sub-family G member 2, Adenosine receptor A3","drug_class":"","quality_score":null,"revenue":null,"mechanism":""},{"drug_id":"omeprazol","indication_name":"Zollinger-Ellison syndrome","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Omeprazol","company_name":"RenJi Hospital","drug_phase":"marketed","molecular_target":"ATP-binding cassette sub-family G member 2, Cytochrome P450 1A2, Cytochrome P450 2C19","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"pantoprazol","indication_name":"Zollinger-Ellison syndrome","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Pantoprazol","company_name":"Northern Orthopaedic Division, Denmark","drug_phase":"marketed","molecular_target":"ATP-binding cassette sub-family G member 2, Fatty acid synthase, Multidrug and toxin extrusion protein 1","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"dexrabeprazole","indication_name":"Zollinger-Ellison syndrome","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Dexpure","generic_name":"dexrabeprazole","company_name":"","drug_phase":"unknown","molecular_target":"Proto-oncogene tyrosine-protein kinase receptor Ret","drug_class":"Proton Pump Inhibitors","quality_score":null,"revenue":null,"mechanism":"Dexpure works by irreversibly inhibiting the H+/K+ ATPase enzyme in the stomach lining, reducing acid production."},{"drug_id":"lansoprazole","indication_name":"Zollinger-Ellison syndrome","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Prevacid","generic_name":"lansoprazole","company_name":"Generic (originally Takeda)","drug_phase":"marketed","molecular_target":"ATP-binding cassette sub-family G member 2, Cytochrome P450 2C19, Cytosolic endo-beta-N-acetylglucosaminidase","drug_class":"Proton pump inhibitor (PPI)","quality_score":null,"revenue":null,"mechanism":"Irreversibly inhibits the gastric proton pump to suppress acid secretion."}],"pipeline":[],"offLabel":[],"totalMarketed":16,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT00001254","title":"Evaluating Pancreatic Tumors in Patients With Zollinger-Ellison Syndrome","phase":"","overall_status":"COMPLETED","enrollment_count":273,"lead_sponsor_name":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","has_results":false},{"nct_id":"NCT00001228","title":"Interferon and Octreotide to Treat Zollinger-Ellison Syndrome and Advanced Non-B Islet Cell Cancer","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":50,"lead_sponsor_name":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","has_results":false},{"nct_id":"NCT02454075","title":"YF476 and Type II Gastric Carcinoids","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":3,"lead_sponsor_name":"Trio Medicines Ltd.","has_results":true},{"nct_id":"NCT00001191","title":"The Use of Oral Omeprazole and Intravenous Pantoprazole in Patients With Hypersecretion of Gastric Acid","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":null,"lead_sponsor_name":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","has_results":false},{"nct_id":"NCT00001241","title":"Treatment of Zollinger-Ellison Syndrome","phase":"","overall_status":"COMPLETED","enrollment_count":null,"lead_sponsor_name":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","has_results":false}],"total":5},"guidelines":[],"source":"Drug Landscape verified database"}